Anti-Cd31 Antibody Market Overview
The Anti-Cd31 Antibody Market was valued at USD 1.0 billion in 2024 and is expected to grow from USD 1.1 billion in 2025 to USD 2.5 billion by 2035, registering a CAGR of 8.3% during the forecast period. Increasing cancer research, rising investments in biotechnology, advances in antibody engineering, and expanding applications in diagnostics and targeted therapies are supporting market growth.
North America represents the leading regional market, with a 2024 valuation of approximately USD 450 million. The region benefits from advanced healthcare infrastructure and significant research activity. Europe is also expanding, while Asia-Pacific offers substantial growth potential due to increasing healthcare expenditure, clinical research, and biotechnology investment.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=572289
Key Companies in the Anti-Cd31 Antibody Market
Cell Signaling Technology
BioRad Laboratories
Abcam
Merck KGaA
Fitzgerald Industries International
CST Biotechnology
Thermo Fisher Scientific
R&D Systems
AntibodiesOnline
Bioss Antibodies
Novus Biologicals
Santa Cruz Biotechnology
The Anti-Cd31 Antibody Market is being driven by increasing research into cancer, inflammatory conditions, cardiovascular diseases, and vascular biology. Rising investments in research and development are supporting the development of advanced antibody products, while improvements in monoclonal antibody engineering are enhancing specificity and consistency. Growing interest in targeted therapies, immunotherapy, personalized medicine, and antibody-based diagnostics is creating additional opportunities.
The market is segmented by application, end user, product type, source, and region. Applications include Cancer Therapy, Autoimmune Diseases, Cardiovascular Diseases, and Transplant Rejection. Cancer Therapy was valued at USD 550 million in 2024 and is projected to reach USD 1.25 billion by 2035. End users include Research Institutes, Pharmaceutical Companies, Academic Institutions, and Clinical Laboratories. Product types comprise Recombinant Anti-CD31 Antibody, Monoclonal Anti-CD31 Antibody, and Polyclonal Anti-CD31 Antibody, while sources include Mouse, Rabbit, Goat, and Human.
Recent Developments and Market Trends:
Thermo Fisher Scientific announced a strategic partnership with Abcam in October 2024 to co-develop and distribute anti-CD31 antibody products for research applications.
Merck KGaA completed an acquisition of CST Biotechnology’s antibody portfolio in January 2025, expanding its antibody and assay capabilities.
Bio-Rad Laboratories launched a new anti-CD31 monoclonal antibody in May 2025 optimized for immunohistochemistry applications.
Increasing cancer research and immunotherapy development are supporting demand for anti-CD31 antibodies.
Advances in monoclonal antibody engineering are improving specificity and expanding potential applications.
Growing interest in personalized medicine is increasing research into biomarkers such as CD31.
Reasons to Buy the Report:
Understand the size and growth outlook of the global Anti-Cd31 Antibody Market.
Analyze applications across cancer therapy, autoimmune diseases, cardiovascular diseases, and transplant rejection.
Evaluate demand among research institutes, pharmaceutical companies, academic institutions, and clinical laboratories.
Examine recombinant, monoclonal, and polyclonal anti-CD31 antibody products.
Assess antibody sources including mouse, rabbit, goat, and human.
Identify leading companies and understand the competitive landscape.
Analyze regional opportunities across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
Understand the impact of cancer prevalence, research investment, antibody engineering, targeted therapies, and diagnostic applications on market development.
Future Outlook:
The Anti-Cd31 Antibody Market is expected to continue expanding through 2035 as research into cancer, vascular biology, immunotherapy, and targeted treatments advances. Increasing biotechnology investment, improvements in antibody engineering, and expanding diagnostic applications are expected to create further opportunities. Growing research activity across emerging markets and continued development of personalized medicine should further support demand for anti-CD31 antibody products.
➤➤Explore Our Latest Related Reports:
